PHF8A (4DO0) Materials & Methods |
Entry Clone Source: Site directed mutagenesis |
SGC Construct ID: PHF8A-c380 |
Final protein sequence (Tag sequence in lowercase): ^ TEV protease recognition site |
Tags and additions: N-terminal, TEV cleavable Hexahistidine/ Thioredoxin tag. Kanamycin resistance. |
Host: BL21(DE3)-R3-pRARE2. |
Growth Medium & Induction Protocol: The construct DNA was transformed into competent cells of the expression strain using the standard heat shock procedure. A colony from the freshly transformed plate was used to inoculate 65 ml of LB containing 50 µg/ml kanamycin and 34 µg/ml chloramphenicol. This was incubated overnight at 37°C. 10mls of starter culture were used to inoculate each litre of LB containing 50 µg/ml kanamycin. The cultures were incubated at 37°C and 180rpm until OD~0.6. The temperature of the incubator was then reduced to 18°C. After 45 minutes, the expression was induced with 0.1 mM IPTG and the culture continued overnight. Cells were pelleted at 4500 rpm for 15 min at 4°C, and stored at -80°C. |
Lysis buffer: 50mM Hepes pH 7.5, 500mM NaCl, 5% Glycerol, 10mM Imidazole |
Column 1: Nickel Sepharose Affinity chromatography |
Column 1 Buffers: |
Column 1 Procedure: Loaded the supernatant onto a 2ml packed Nickel sepharose column which had been pre-equilibrated with Lysis buffer. Collected the flow through. The column was then washed with:
The fractions were analysed by SDS-PAGE. |
Column 2: Gel Filtration Chromatography - Hiload Superdex 200 16/60 (GE Healthcare) - 120 ml volume |
Column 2 Buffers: |
Column 2 Procedure: The column was pre-equilibrated with Gel Filtration Buffer. The first two Ni-sepharose eluants were concentrated to 5 ml using an Amicon 30kDa MW cut off centrifugal filter, then filtered through a 0.22 µM PVDF filter. The sample was then loaded onto the column using an AKTA express system at a flow rate of 1.2 ml/min and collected in 1.8ml fractions. The protein-containing fractions were analysed by SDS-PAGE. |
Enzymatic treatment: PTEV protease digestion Fractions from the gel filtration were pooled and the N-terminal histidine-thioredoxin tag was cleaved using 150 µg TEV protease per 10mg of protein at 4°C overnight. SDS-PAGE was used to confirm the cleavage of the protein. |
Column 3: Nickel Sepharose Rebinding and TEV clean-up The his-TEV and other contaminants were separated from the protein by applying the sample to a 250µl Ni-sepharose column pre-equilibrated with GF buffer. The column was washed with GF buffer, lysis buffer and elution buffer. SDS-PAGE showed that the flow through and lysis buffer washes contained the TEV-cleaved protein. These were pooled together. |
Column 4: Hi-Prep 26/10 Desalting column (GE Healthcare) |
Column 4 Buffers: |
Column 4 Procedure: The desalting column was used to buffer exchange the protein into low salt buffer on an AKTA purifier system. |
Column 5: Hi-Trap 5ml Sepharose Q HP (GE Healthcare) The desalted sample was loaded onto the above column using an AKTA purifier system and the flow through was collected. The protein was then eluted with a salt gradient of 0-25% of 2M NaCl in 25 column volumes and collected in 1.5ml fractions. The eluted protein fractions were analysed on SDS-PAGE and pooled together. |
Column 6: Nickel Sepharose Rebinding The pooled fractions were passed through another 250µl nickel sepharose column using exactly the same procedure as for column 3 earlier. This resulted in a slightly cleaner protein. The flow through and wash fractions were then pooled and concentrated to 12.4 mg/ml using an Amicon 30kDa MW cut off centrifugal filter. Glycerol was added to a final concentration of 5%. |
Mass spec characterization: |
Crystallization: Crystals of PHF8.Daminozide were grown by vapour diffusion at 4°C in sitting drops. The protein and Daminozide were mixed at a molar ratio of 1:5 prior to crystallisation and crystals were obtained by mixing 100 nl thereof and 50 nl of a precipitant consisting of 0.1 M sodium acetate pH 4.5, 2.25M ammonium sulphate. |
Data Collection: |